

In the claims:

For the convenience of the Examiner, all claims being examined, whether or not amended, are presented below.

1-50. (Cancelled)

51. (Currently amended) A purified preparation of an antibody, or an antigen binding domain thereof, which is specifically binds to ~~immunoreactive with~~ a mammalian RAPT1 protein and does not substantially cross react with a fungal TOR1 or TOR2 protein.
52. (Currently amended) A polyclonal antibody preparation enriched for antibodies which specifically ~~immunoreactive with~~ bind to a mammalian RAPT1 protein.
53. (Currently amended) A monoclonal antibody composition including a monoclonal antibody, or an antigen binding domain thereof, which is specifically binds to ~~immunoreactive with~~ a mammalian RAPT1 protein and does not substantially cross react with a fungal TOR1 or TOR2 protein.
54. (Currently amended) A recombinant antibody including an antigen binding domain which is specifically binds to ~~immunoreactive with~~ a mammalian RAPT1 protein and does not substantially cross react with a fungal TOR1 or TOR2 protein.
55. (Currently amended) The preparation of claim 51, wherein the antibody binds to ~~is immunoreactive with~~ a RAPT1 protein having an amino acid sequence at least 90 percent identical to the sequence of SEQ ID No. 12.
56. (Previously added) The preparation of claim 55, wherein the antibody has a binding affinity of less than 10 percent for a yeast TOR1 or TOR2 protein.

57. **(Currently amended)** The preparation of claim 52, enriched for antibodies ~~immunoreactive with~~ which bind to a RAPT1 protein having an amino acid sequence at least 90 percent identical to the sequence of SEQ ID No. 12.
58. **(Previously added)** The preparation of claim 57 wherein the preparation has a binding affinity of less than 10 percent for a yeast TOR1 or TOR2 protein.
59. **(Currently amended)** The preparation of claim 53, wherein the monoclonal antibody binds to ~~is immunoreactive with~~ a RAPT1 protein having an amino acid sequence at least 90 percent identical to the sequence of SEQ ID No. 12.
60. **(Previously added)** The preparation of claim 59, wherein the antibody has a binding affinity of less than 10 percent for a yeast TOR1 or TOR2 protein.
61. **(Currently amended)** The preparation of claim 54, wherein the antigen binding domain binds to ~~is immunoreactive with~~ a RAPT1 protein having an amino acid sequence at least 90 percent identical to the sequence of SEQ ID No. 12.
62. **(Previously added)** The preparation of claim 61, wherein the antibody has a binding affinity of less than 10 percent for a yeast TOR1 or TOR2 protein.